Entero Therapeutics Inc.
0.59
0.00 (0.20%)
At close: Jan 14, 2025, 3:58 PM
0.56
-5.85%
After-hours Jan 14, 2025, 03:59 PM EST

Company Description

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.

Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.

It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients.

The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021.

First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Entero Therapeutics Inc.
Entero Therapeutics Inc. logo
Country United States
IPO Date Oct 11, 2016
Industry Biotechnology
Sector Healthcare
Employees 9
CEO James R. Sapirstein M.B.A., R.Ph.

Contact Details

Address:
777 Yamato Road
Boca Raton, Florida
United States
Website https://www.firstwavebio.com

Stock Details

Ticker Symbol n/a
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code n/a
CUSIP Number n/a
ISIN Number US33749P4081
Employer ID -
SIC Code n/a

Key Executives

Name Position
James R. Sapirstein M.B.A., R.Ph. Chief Executive Officer & Chairman
Sarah Romano CPA Chief Financial Officer
Amy Chandler-Skerkis Vice President of Regulatory Affairs, QA & Compliance
Jennifer A. Sealey-Voyksner Ph.D. Senior Vice President for Research & Development
Martin Krusin M.B.A. Senior Vice President of Corporate Development

Latest SEC Filings

No SEC filings available.